Targeted Disruption of Bone Marrow Stromal Cell-Derived Gremlin1 Limits Multiple Myeloma Disease Progression In Vivo
- Supplementary File 1:
PDF-Document (PDF, 633 KiB)
Clark, K.C.; Hewett, D.R.; Panagopoulos, V.; Plakhova, N.; Opperman, K.S.; Bradey, A.L.; Mrozik, K.M.; Vandyke, K.; Mukherjee, S.; Davies, G.C.G.; Worthley, D.L.; Zannettino, A.C.W. Targeted Disruption of Bone Marrow Stromal Cell-Derived Gremlin1 Limits Multiple Myeloma Disease Progression In Vivo. Cancers 2020, 12, 2149. https://doi.org/10.3390/cancers12082149
Clark KC, Hewett DR, Panagopoulos V, Plakhova N, Opperman KS, Bradey AL, Mrozik KM, Vandyke K, Mukherjee S, Davies GCG, Worthley DL, Zannettino ACW. Targeted Disruption of Bone Marrow Stromal Cell-Derived Gremlin1 Limits Multiple Myeloma Disease Progression In Vivo. Cancers. 2020; 12(8):2149. https://doi.org/10.3390/cancers12082149
Chicago/Turabian StyleClark, Kimberley C., Duncan R. Hewett, Vasilios Panagopoulos, Natalya Plakhova, Khatora S. Opperman, Alanah L. Bradey, Krzysztof M. Mrozik, Kate Vandyke, Siddhartha Mukherjee, Gareth C.G. Davies, Daniel L. Worthley, and Andrew C.W. Zannettino. 2020. "Targeted Disruption of Bone Marrow Stromal Cell-Derived Gremlin1 Limits Multiple Myeloma Disease Progression In Vivo" Cancers 12, no. 8: 2149. https://doi.org/10.3390/cancers12082149